{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.6","upperLimit":"83.7","value":"69.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The time from the first dose date to the first observation of a disease progression or death due to any cause by 6 mo. Disease progression was assessed radiologically per RECIST v1.1, and was defined as ≥20% increase in the sum of diameters of target lesions, and absolute increase of ≥5 mm. PFS rate at 6 months was summarized using Kaplan-Meier methods (percentage rounded up to 1 digit decimal).","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with malignant PEComa were treated with 100 mg/m2 nab-sirolimus (30 mins IV infusion) on Days 1 and 8 in a 21-day cycle","id":"OG000","title":"Experimental: Nab-Sirolimus"}],"paramType":"NUMBER","populationDescription":"Efficacy Evaluable Patient Population","reportingStatus":"POSTED","timeFrame":"6 months","title":"Progression-free Survival Rate at 6 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}